[go: up one dir, main page]

HK1118209A1 - Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid - Google Patents

Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid

Info

Publication number
HK1118209A1
HK1118209A1 HK08109378.5A HK08109378A HK1118209A1 HK 1118209 A1 HK1118209 A1 HK 1118209A1 HK 08109378 A HK08109378 A HK 08109378A HK 1118209 A1 HK1118209 A1 HK 1118209A1
Authority
HK
Hong Kong
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
HK08109378.5A
Other languages
English (en)
Inventor
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Astrazeneca Ab
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Astrazeneca Ab, Univ Aberdeen filed Critical Astrazeneca Ab
Publication of HK1118209A1 publication Critical patent/HK1118209A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08109378.5A 1999-02-06 2008-08-21 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid HK1118209A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1118209A1 true HK1118209A1 (en) 2009-02-06

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02103012A HK1041223A1 (en) 1999-02-06 2002-04-22 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicamentfor the treatment of diabetic neuropathy
HK08109378.5A HK1118209A1 (en) 1999-02-06 2008-08-21 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK02103012A HK1041223A1 (en) 1999-02-06 2002-04-22 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicamentfor the treatment of diabetic neuropathy

Country Status (34)

Country Link
US (4) US6894058B1 (xx)
EP (2) EP1897546B1 (xx)
JP (3) JP2002536332A (xx)
KR (1) KR100699757B1 (xx)
CN (1) CN1196488C (xx)
AR (1) AR025512A1 (xx)
AT (2) ATE367162T1 (xx)
AU (1) AU763970B2 (xx)
BR (1) BR0007996A (xx)
CA (1) CA2368186C (xx)
CY (2) CY1106879T1 (xx)
CZ (2) CZ302893B6 (xx)
DE (2) DE60045168D1 (xx)
DK (2) DK1150678T3 (xx)
EE (2) EE05556B1 (xx)
ES (2) ES2352803T3 (xx)
GB (1) GB0001662D0 (xx)
HK (2) HK1041223A1 (xx)
HU (1) HU227642B1 (xx)
IL (3) IL144730A0 (xx)
IS (2) IS2793B (xx)
MX (1) MXPA01007821A (xx)
MY (1) MY138289A (xx)
NO (1) NO330400B1 (xx)
NZ (3) NZ525419A (xx)
PL (1) PL198098B1 (xx)
PT (2) PT1150678E (xx)
RU (1) RU2239456C2 (xx)
SI (2) SI1897546T1 (xx)
SK (2) SK286854B6 (xx)
TR (1) TR200102229T2 (xx)
TW (1) TWI230067B (xx)
WO (1) WO2000045818A1 (xx)
ZA (1) ZA200105885B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
AU7649100A (en) 1999-08-30 2001-03-26 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
CA2424060A1 (en) * 2000-10-12 2003-03-31 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
WO2002032411A2 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
AU2002215160A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
TW200305415A (en) * 2002-03-22 2003-11-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
CA2524175C (en) 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
PL1643999T3 (pl) * 2003-06-20 2012-02-29 Nephrogenex Inc Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
CN102216281B (zh) 2008-09-06 2014-11-05 碧奥尼维亚制药股份有限公司 依帕司他的新胆碱共结晶
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
DE69325574T2 (de) 1992-04-13 2000-03-16 Zeneca Ltd. ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
WO1995026188A1 (en) 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1813286A3 (en) 1996-04-05 2008-04-16 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
PL350312A1 (en) 2002-12-02
ES2286995T3 (es) 2007-12-16
SI1897546T1 (sl) 2011-02-28
CY1106879T1 (el) 2012-05-23
ZA200105885B (en) 2002-10-17
CA2368186A1 (en) 2000-08-10
SK286854B6 (sk) 2009-06-05
NO20013812L (no) 2001-10-02
KR100699757B1 (ko) 2007-03-27
NZ513061A (en) 2003-06-30
CZ302881B6 (cs) 2012-01-04
EP1150678B1 (en) 2007-07-18
NZ525419A (en) 2004-12-24
PL198098B1 (pl) 2008-05-30
EP1897546A1 (en) 2008-03-12
CN1196488C (zh) 2005-04-13
CY1110992T1 (el) 2015-06-11
IS2820B (is) 2012-12-15
RU2239456C2 (ru) 2004-11-10
AU2304700A (en) 2000-08-25
CZ302893B6 (cs) 2012-01-11
IL208330A0 (en) 2010-12-30
EP1897546B1 (en) 2010-10-27
CA2368186C (en) 2008-06-03
DE60045168D1 (de) 2010-12-09
IL144730A (en) 2010-12-30
NO330400B1 (no) 2011-04-04
IS6016A (is) 2001-07-20
EE200100405A (et) 2002-10-15
MXPA01007821A (es) 2004-08-19
MY138289A (en) 2009-05-29
TWI230067B (en) 2005-04-01
IS2793B (is) 2012-08-15
EP1150678A1 (en) 2001-11-07
IS8978A (is) 2011-08-23
PT1897546E (pt) 2010-12-15
AU763970B2 (en) 2003-08-07
CN1338937A (zh) 2002-03-06
HUP0105138A2 (hu) 2002-04-29
HK1041223A1 (en) 2002-07-05
ATE485823T1 (de) 2010-11-15
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
SK287792B6 (sk) 2011-10-04
US20050209128A1 (en) 2005-09-22
DK1150678T3 (da) 2007-10-08
ES2352803T3 (es) 2011-02-23
SK11102001A3 (sk) 2002-05-09
GB0001662D0 (en) 2000-03-15
EE201200015A (et) 2012-10-15
EE05556B1 (et) 2012-08-15
WO2000045818A1 (en) 2000-08-10
TR200102229T2 (tr) 2001-12-21
EE05621B1 (et) 2013-02-15
HUP0105138A3 (en) 2002-11-28
US20120041010A1 (en) 2012-02-16
PT1150678E (pt) 2007-09-14
IL144730A0 (en) 2002-06-30
HU227642B1 (en) 2011-10-28
DE60035575T2 (de) 2008-04-03
JP2012051898A (ja) 2012-03-15
KR20010089635A (ko) 2001-10-06
JP2002536332A (ja) 2002-10-29
BR0007996A (pt) 2001-10-30
DE60035575D1 (de) 2007-08-30
SI1150678T1 (sl) 2008-02-29
CZ20012806A3 (cs) 2002-02-13
DK1897546T3 (da) 2011-01-17
US6894058B1 (en) 2005-05-17
JP2014065718A (ja) 2014-04-17
NZ536433A (en) 2006-08-31
ATE367162T1 (de) 2007-08-15
AR025512A1 (es) 2002-12-04

Similar Documents

Publication Publication Date Title
HK1118209A1 (en) Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid
ZA200205331B (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid.
EE05586B1 (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IL175086A0 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
IS6009A (is) Lyfjablöndur sem samanstanda af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýruog lata, vaka eða hvarfefni af P450 ísóensími 3A4
IL174073A0 (en) Crystalline form of bis [(e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl (methylsulphonyl) amino] pyrimidin - 5 - yl] (3r,5s) - 3,5 - dihydroxyhept - 6 - enoic acid] calcium salt
HUP0104828A3 (en) Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego